Sökning: onr:"swepub:oai:DiVA.org:uu-393649" >
Low-molecular-weigh...
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)
-
- Gezelius, E. (författare)
- Lund University,Lunds universitet,Tumörmikromiljön,Forskargrupper vid Lunds universitet,Tumor microenvironment,Lund University Research Groups,Skåne University Hospital
-
- Bendahl, P. O. (författare)
- Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,The Liquid Biopsy och Tumörprogression i Bröstcancer,Personalized Breast Cancer Treatment,Lund University Research Groups,The Liquid Biopsy and Tumor Progression in Breast Cancer
-
- Gonçalves de Oliveira, K. (författare)
- Lund University,Lunds universitet,Tumörmikromiljön,Forskargrupper vid Lunds universitet,Tumor microenvironment,Lund University Research Groups
-
visa fler...
-
- Ek, L. (författare)
- Skane Univ Hosp, Dept Resp Med, Entregatan 7, SE-22185 Lund, Sweden,Skåne University Hospital
-
- Bergman, B. (författare)
- Sahlgrens Univ Hosp, Dept Resp Med, SE-41345 Gothenburg, Sweden,Sahlgrenska University Hospital
-
- Sundberg, J. (författare)
- Skane Univ Hosp, Dept Hematol Radiophys & Oncol, Lasarettsgatan 23A, SE-22185 Lund, Sweden,Skåne University Hospital
-
- Strandberg, K. (författare)
- Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups
-
- Kraemer, R. (författare)
- Heidelberg Univ, Inorgan Chem Inst, Neuenheimer Feld 270, D-60129 Heidelberg, Germany,Heidelberg University
-
- Belting, Mattias (författare)
- Uppsala University,Lund University,Lunds universitet,Uppsala universitet,Neuroonkologi,Lund Univ, Div Oncol, Dept Clin Sci, Barngatan 4, SE-22185 Lund, Sweden;Skane Univ Hosp, Dept Hematol Radiophys & Oncol, Lasarettsgatan 23A, SE-22185 Lund, Sweden,Tumörmikromiljön,Forskargrupper vid Lunds universitet,Tumor microenvironment,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- ELSEVIER SCI LTD, 2019
- 2019
- Engelska.
-
Ingår i: European Journal of Cancer. - : ELSEVIER SCI LTD. - 0959-8049 .- 1879-0852. ; 118, s. 82-90
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
http://www.ejcancer....
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin Red assay to objectively assess adherence and how this associates with the patient outcome in the RASTEN trial. Methods: RASTEN is a multicentre, randomised phase III trial investigating if the addition of LMWH to standard therapy can improve survival in small-cell lung cancer. LMWH was measured in plasma (N = 258) by the Heparin Red assay and compared with the anti-factor Xa (anti-FXa) activity assay. Results: Both methods could differentiate patients in the LMWH arm from the control arm and patients receiving therapeutic LMWH owing to thrombosis. Receiver Operating Characteristic (ROC) analysis yielded adherence rates of 85% for anti-FXa and 68% for Heparin Red. No survival benefits were found in the adherent subgroup compared with the control arm (hazard ratio [HR]: 1.26; 95% confidence interval [CI]: 0.95-1.67; P = 0.105 and HR: 1.19; 95% CI: 0.89-1.60; P = 0.248 for anti-FXa and Heparin Red, respectively). Heparin Red could define patients with high probability of adherence to LMWH treatment, which warrants prospective studies for further validation. Our finding that the LMWH-adherent subpopulation did not show improved survival excludes that the negative outcome of RASTEN was due to poor adherence. (C) 2019 The Authors. Published by Elsevier Ltd.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Anticoagulant therapy adherence
- Heparin assays
- Lung cancer
- Anticoagulant therapy adherence
- Heparin assays
- Lung cancer
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas